Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.

[1]  A. Jakubowiak,et al.  Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. , 2022, JAMA oncology.

[2]  P. Hari,et al.  Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Oriol,et al.  Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial , 2021, Blood.

[4]  M. Dimopoulos,et al.  Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Morgan,et al.  International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials , 2020, Leukemia.

[6]  K. Griffith,et al.  Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. , 2020, Blood.

[7]  N. Geller,et al.  Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). , 2020 .

[8]  A. Jakubowiak,et al.  Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. , 2020, Blood.

[9]  P. Sonneveld,et al.  Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study , 2019, The Lancet.

[10]  N. Geller,et al.  Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Morgan,et al.  Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial , 2019, The Lancet. Oncology.

[12]  M. Dimopoulos,et al.  Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial , 2019, The Lancet.

[13]  Sin-Ho Jung,et al.  Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Sullivan,et al.  Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  A. Oriol,et al.  Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial , 2017, Leukemia.

[16]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[17]  T. Kalina,et al.  EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols , 2012, Leukemia.

[18]  B. Pégourié,et al.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[19]  K. Owzar,et al.  Lenalidomide after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[20]  M. Terol,et al.  High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. , 2012, Blood.

[21]  Serge Leyvraz,et al.  Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.

[22]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.